NY-PHILIP-MORRIS-INTL
9.10.2020 08:29:10 CEST | Business Wire | Press release
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Jennifer Motles to the position of Chief Sustainability Officer, effective November 1, 2020. Ms. Motles will succeed current CSO Huub Savelkouls, who will retire after almost three decades of distinguished service.
Ms. Motles will report to the company’s CFO, Emmanuel Babeau, as it is increasingly recognized—by both companies and investors—that fully integrating environmental, social, and governance (ESG) drivers into business strategy can significantly enhance both the sustainability agendas and financial performance.
“Integrating sustainability and financial strategies is further recognition of our commitment to unsmoking our planet and transforming our company,” said PMI’s CEO, André Calantzopoulos. “It is a logical next step for us, following our Statement of Purpose adopted by our Board and the introduction of Integrated Reporting earlier this year.”
Ms. Motles joined PMI in 2015, when she helped craft PMI’s sustainability strategy, ensuring it was intrinsically linked to the adoption of the company’s vision of delivering a smoke-free future. Since then, she has helped advance PMI’s transformation, honing the company’s sustainability and ESG performance, with a strong focus on shareholder and stakeholder engagement.
“This move outlines that ESG is core to PMI’s performance and success, and further demonstrates PMI’s leadership in sustainability and corporate purpose,” said Mr. Babeau. “Jennifer, with her broad range of international experience and her proven track record in the domain, is the ideal candidate to lead our company’s ambitious sustainability agenda.”
“It is our firm belief that sustainability and business performance do not follow separate paths and narratives. They are fully interrelated and mutually reinforcing and should be organized and presented to all stakeholders in an integrated way,” continued Mr. Babeau.
Addressing the health impacts of cigarettes while working relentlessly to convince the hundreds of millions of men and women who would otherwise continue smoking to switch to noncombustible and therefore smoke-free alternatives is the most important contribution we can make to a sustainable world and to a sustainable PMI. This monumental effort is the cornerstone of PMI’s purpose and business strategy. PMI’s hopes and ambition are that all stakeholders of the company will embrace and support this mission.
Ms. Motles began her career working for the Chilean Office of Drugs & Crime Prevention and Prosecution. She gained international experience working for organizations such as UNCITRAL, UNODC’s Terrorism Prevention Branch, and the UNCTAD/WTO’s International Trade Center. Prior to joining PMI, Jennifer worked for the government of Israel, representing the country as its Human Rights & Humanitarian Affairs Officer at the United Nations and other international organizations.
She holds a JD degree from Universidad de Chile—Escuela de Derecho, and an LLM degree from University of California, Berkeley School of Law, as well as specialized diplomas in Women’s Human Rights, Behavioral Economics, Sustainability, Sustainable Finance, and Political Affairs from IHEID, Harvard Business School, the Harvard School of Public Health, and Stanford University.
“This announcement wouldn’t be complete without acknowledging our gratitude to Huub for his many accomplishments,” added Mr. Calantzopoulos. “In honor of his retirement, we celebrate him and wish him the best in his next chapter.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005939/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
